Comera Life Sciences Holdings Overview
- Year Founded
-
2014
- Status
-
Acquired/Merged
- Employees
-
16
- Latest Deal Type
-
PIPE
- Latest Deal Amount
-
$4.1M
- Investors
-
3
Comera Life Sciences Holdings General Information
Description
Comera Life Sciences Holdings Inc is a pre-clinical biotechnology company dedicated to promoting formulation science and technology to transform essential biologic medicines from intravenous to subcutaneous forms. Comera's internal portfolio of proprietary techniques known as the SQore platform is designed to potentially transform essential biologic medicines from intravenous (IV) to subcutaneous (SQ) forms, and optimize current versions of subcutaneous biologics, and produce biosimilar versions of existing subcutaneous products. It also collaborates with pharmaceutical and biotechnology companies, applying the SQore platform to the Company's partners' biologic medicines to deliver enhanced formulations that facilitate self-injectable care.
Contact Information
Website
www.comeralifesciences.comCorporate Office
- 12 Gill Street
- Suite 4650
- Woburn, MA 01801
- United States
Corporate Office
- 12 Gill Street
- Suite 4650
- Woburn, MA 01801
- United States
Comera Life Sciences Holdings Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. PIPE | 12-Sep-2023 | $4.1M | Completed | Generating Revenue | ||
| 6. PIPE | 04-Jan-2023 | Completed | Generating Revenue | |||
| 5. PIPE | 31-Aug-2022 | Completed | Generating Revenue | |||
| 4. PIPE | 20-May-2022 | Completed | Generating Revenue | |||
| 3. Reverse Merger | 19-May-2022 | Completed | Generating Revenue | |||
| 2. Later Stage VC (Series B) | 21-Jul-2021 | $10M | $24.6M | Completed | Pre-Clinical Trials | |
| 1. Early Stage VC (Series A) | 04-Apr-2018 | $14.6M | $14.6M | Completed | Startup |
Comera Life Sciences Holdings Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A-6 | ||||||||
| Series A-5 | ||||||||
| Series A-4 | ||||||||
| Series A-3 | ||||||||
| Series A-2 | 1,266,667 | $0.001000 | $1.5 | $1.5 | 1x | $1.5 | 6.67% | |
| Series A-1 | 6,000,000 | $0.001000 | $1 | $1 | 1x | $1 | 31.6% |
Comera Life Sciences Holdings Comparisons
Industry
Financing
Details
Comera Life Sciences Holdings Competitors (7)
One of Comera Life Sciences Holdings’s 7 competitors is Halozyme Therapeutics, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Halozyme Therapeutics | Formerly VC-backed | San Diego, CA | ||||
| Rani Therapeutics | Formerly VC-backed | San Jose, CA | ||||
| Lindy Biosciences | Venture Capital-Backed | Morrisville, NC | ||||
| Athos Therapeutics | Venture Capital-Backed | Los Angeles, CA | ||||
| Alteogen | Formerly VC-backed | Daejeon, South Korea |
Comera Life Sciences Holdings Patents
Comera Life Sciences Holdings Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023091370-A1 | Excipient compounds for biopolymer formulations | Inactive | 16-Nov-2021 | ||
| EP-4210757-A2 | Excipient compounds for protein formulations | Inactive | 11-Sep-2020 | ||
| EP-4210757-A4 | Excipient compounds for protein formulations | Inactive | 11-Sep-2020 | ||
| US-20250186600-A1 | Excipient compounds for protein formulations | Inactive | 11-Sep-2020 | ||
| WO-2022056220-A2 | Excipient compounds for protein formulations | Inactive | 11-Sep-2020 | A61K39/39591 |
Comera Life Sciences Holdings Signals
Comera Life Sciences Holdings Former Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Arena Investors | PE/Buyout | Minority | ||
| KBI BioPharma | Corporation | Minority | ||
| Life Science Venture Capital | Corporate Venture Capital | Minority | ||
| Phoenix Venture Partners | Venture Capital | Minority |
Comera Life Sciences Holdings Acquisitions (1)
Comera Life Sciences Holdings’s most recent deal was a Merger/Acquisition with OTR Acquisition. The deal was made on 19-May-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| OTR Acquisition | 19-May-2022 | Merger/Acquisition | Special Purpose Acquisition Company (SPAC) |
Comera Life Sciences Holdings ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
Comera Life Sciences Holdings FAQs
-
When was Comera Life Sciences Holdings founded?
Comera Life Sciences Holdings was founded in 2014.
-
Where is Comera Life Sciences Holdings headquartered?
Comera Life Sciences Holdings is headquartered in Woburn, MA.
-
What is the size of Comera Life Sciences Holdings?
Comera Life Sciences Holdings has 16 total employees.
-
What industry is Comera Life Sciences Holdings in?
Comera Life Sciences Holdings’s primary industry is Biotechnology.
-
Is Comera Life Sciences Holdings a private or public company?
Comera Life Sciences Holdings is a Private company.
-
What is Comera Life Sciences Holdings’s current revenue?
The current revenue for Comera Life Sciences Holdings is .
-
How much funding has Comera Life Sciences Holdings raised over time?
Comera Life Sciences Holdings has raised $48.3M.
-
Who are Comera Life Sciences Holdings’s investors?
Arena Investors, KBI BioPharma, Life Science Venture Capital, and Phoenix Venture Partners have invested in Comera Life Sciences Holdings.
-
Who are Comera Life Sciences Holdings’s competitors?
Halozyme Therapeutics, Rani Therapeutics, Lindy Biosciences, Athos Therapeutics, and Alteogen are some of the 7 competitors of Comera Life Sciences Holdings.
-
When was Comera Life Sciences Holdings acquired?
Comera Life Sciences Holdings was acquired on 12-Sep-2023.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process